Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
21.53
+0.62 (2.97%)
Apr 8, 2026, 11:06 AM EDT - Market open
Neurogene Employees
Neurogene had 131 employees as of December 31, 2025. The number of employees increased by 24 or 22.43% compared to the previous year.
Employees
131
Change (1Y)
24
Growth (1Y)
22.43%
Revenue / Employee
n/a
Profits / Employee
-$689,702
Market Cap
335.32M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 131 | 24 | 22.43% |
| Dec 31, 2024 | 107 | 16 | 17.58% |
| Dec 31, 2023 | 91 | 9 | 10.98% |
| Jun 30, 2023 | 82 | - | - |
| Dec 31, 2022 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 179 |
| LENZ Therapeutics | 152 |
| Adlai Nortye | 123 |
| Prelude Therapeutics | 79 |
| Rezolute | 75 |
| Surrozen | 44 |
| Inhibikase Therapeutics | 35 |
| Climb Bio | 29 |
NGNE News
- 15 days ago - Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates - Business Wire
- 4 weeks ago - Neurogene to Participate in Stifel 2026 Virtual CNS Forum - Business Wire
- 5 weeks ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome - Business Wire
- 2 months ago - Neurogene to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - Business Wire
- 3 months ago - Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire